Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children

Ibrahim Ince, PhD, André Dallmann, PhD, Sebastian Frechen, MD, Katrin Coboeken, PhD, Christoph Niederalt, PhD, Thomas Wendl, PhD, Michael Block, PhD, Michaela Meyer, PhD, Thomas Eissing, PhD, Rolf Burghaus, PhD, Jörg Lippert, PhD, Stefan Willmann, PhD, and Jan-Frederik Schlender, PhD

Abstract

Development and guidance of dosing schemes in children have been supported by physiology-based pharmacokinetic (PBPK) modeling for many years. PBPK models are built on a generic basis, where compound- and system-specific parameters are separated and can be exchanged, allowing the translation of these models from adults to children by accounting for physiological differences. Owing to these features, PBPK modeling is a valuable approach to support clinical decision making for dosing in children. In this analysis, we evaluate pediatric PBPK models for 10 small-molecule compounds that were applied to support clinical decision processes at Bayer for their predictive power in different age groups. Ratios of PBPK-predicted to observed PK parameters for the evaluated drugs in different pediatric age groups were estimated. Predictive performance was analyzed on the basis of a 2-fold error range and the bioequivalence range (ie, 0.8 ≤ predicted/observed ≤ 1.25). For all 10 compounds, all predicted-to-observed PK ratios were within a 2-fold error range (n = 27), with two-thirds of the ratios within the bioequivalence range (n = 18). The findings demonstrate that the pharmacokinetics of these compounds was successfully and adequately predicted in different pediatric age groups. This illustrates the applicability of PBPK for guiding dosing schemes in the pediatric population.

Keywords

clinical trials (CTR), dose prediction, PBPK, pediatrics (PED), physiology (PHY)

During the past 15 years, physiology-based pharmacokinetic (PBPK) modeling has been the scientific foundation to match the exposure in a pediatric population to the target exposure, that is, a known reference exposure clinically observed in an adult patient population at a safe and efficacious dose. PBPK models are mechanistic models that separate compound-specific properties (such as lipophilicity and molecular weight) from system-specific parameters (such as organ volumes and blood flows). Therefore, PBPK models are built on a generic basis and can be reparameterized, allowing the translation to a population with a different physiology. Because of these features, PBPK modeling is an increasingly popular approach to support decision making for dosing in relevant subpopulations of special clinical interest, such as children. This is also supported by regulatory authorities.1,2

PBPK models incorporate age-dependent changes of relevant anthropometric and physiological parameters and apply ontogeny and variability of active processes involved in the absorption, distribution, metabolism, and elimination of pharmaceutical compounds.3,4 As most of these changes occur in the first 2 years of life, such as maturation of the liver and kidney function, in contrast to other changes that occur later in a child’s life, for example, during puberty, a good understanding of this age dependency is of utmost importance. An overview of relevant processes and properties that are known, less known, or need further elucidation has been previously described.5

Already in the early phase of drug development in adults, dosing in children is discussed. In the absence of clinical data in children, a PBPK model is first built based on physicochemical information and concentration-time data from adult pharmacokinetic (PK) studies. As a next step, the translation of the adult...
PBPK model to children—initially purely predictive—is made on the basis of the existing knowledge on age-related anthropometry, physiology, and active processes, such as enzyme and transporter activities. Subsequently, when clinical data become available during the pediatric development program, PBPK-based predictions transition into a descriptive mode as the PBPK model may be refined and is used to integrate and interpret the observed clinical data.

To date, PBPK predictions from several studies informed dosing decisions and streamlined the clinical study design for 10 Bayer small-molecule compounds. In this analysis, we evaluate the predictive performance of pediatric PBPK models for these compounds in different age groups. These models were applied to support clinical decision processes, such as identifying dose levels and dosing intervals, sampling schemes, and cohort sizes.

**Methods**

The workflow for constructing and translating a PBPK model from adults to children is well described. An overview of relevant building blocks to construct a PBPK model for adults and the parameters adjusted during translation to children for use in pediatric clinical development is exemplarily illustrated in Figure 1. The building blocks of a PBPK model are categorized into drug- and system-specific properties, study protocol, and formulation characteristics. Some parameters are dependent on a combination of both drug- and physiology-specific parameters (drug-biology interaction), such as fraction unbound or membrane permeability. For the parameterization of the adult and pediatric PBPK models and for the simulation of PK parameters of 10 small-molecule Bayer compounds, the existing model for each compound was applied for this analysis (Table 1). The PBPK models for amikacin, gadovist, and magnevist were updated to PK-Sim version 9 as additional simulations needed to be performed for this analysis, which is described in more detail below. As the developed PBPK models that were applied for clinical decision making have been filed for regulatory request, most of these models are also already published, whereas some of them are still part of the ongoing drug development program.

To evaluate the predictive performance of the PBPK models, we calculated the ratio of PK parameters for each compound was calculated and categorized into the predefined age groups. This ratio was calculated using the ratio of PK parameters predicted by PBPK before study conduct vs PK parameters estimated by population pharmacokinetics (PopPK) and noncompartmental analysis (NCA) post hoc as clinical pediatric study data became available. For clinical studies in children, especially when small children are included, the collected data are typically very sparse, and PopPK assessment was preferred over NCA for comparison. However, PopPK-derived PK parameters were not always available (eg, for amikacin, riociguat). The aggregation of PK parameters derived from PBPK and PopPK simulations is outlined below for each compound. Integral exposure measures, clearance, or concentrations at specific times after dosing were explored depending on the availability of pediatric study data per compound. The PK parameters for each compound were selected on the basis of the relevant primary PK parameter applied for the respective analyses for calculating pediatric doses.

The ratio of the PK parameters for each compound was calculated and categorized into the predefined age groups.
An Overview of 10 Small-Molecule Bayer Compounds Applied in Children Since 2005, the Age Ranges of Children With Available Clinical Data, and the Clearance Processes Included in the PBPK Model

| Compound Name | Age Range, y | Source Published Clinical Data | Involved Processes in PBPK Model | Route of Administration In Children |
|---------------|--------------|--------------------------------|----------------------------------|------------------------------------|
| Amikacin      | 0.01-16      | 27,28                          | GFR                              | IV                                 |
| Ciprofloxacin  | 0.2-6.6      | 36,37                          | CYP1A2, TS, GFR, Bil.CL           | PO                                 |
| Copanlisib    | 13-17        | ...                            | CYP3A4, P-gp, BP                  | IV                                 |
| Gadovist      | 0.2-18       | 38,39                          | GFR                              | IV                                 |
| Levonorgestrel| 12-18        | ...                            | Hepatic clearance                 | IU                                 |
| Magnevist     | 0.2-2        | 44,45                          | GFR                              | IV                                 |
| Moxifloxacin  | 0-18         | 44,45                          | CYP1A1, SULT2A1, Bil.CL, GFR      | PO                                 |
| Regorafenib   | 2-17         | 47                             | CYP3A4, UGT1A9, Bil.CL            | PO                                 |
| Rivaroxaban   | 0.5-18       | 52                             | CYP3A4, Plasma Hydrolysis, GFR, TS | PO                                 |

BCRP, breast cancer resistance protein; Bil.CL, biliary clearance; BP, hypothetical binding partner; CYP, cytochrome P450; GFR, glomerular filtration rate; IU, intrauterine; IV, intravenous; P-gp, P-glycoprotein; PO, per os; SULT, sulfotransferase; TS, tubular secretion; UGT, uridine 5'-diphospho-glucuronosyltransferase.

Data

An overview of Bayer small-molecule compounds applied in this analysis is shown in Table 1. This table also illustrates the available clinical data for the compounds, including the age ranges of children that were used in this analysis. Compounds were considered for this retrospective analysis in case clinical data has already been obtained in pediatric age groups.

Software

All PBPK models were built using the Open Systems Pharmacology (OSP) software, formerly known as commercial software tools PK-Sim and MoBi, which is now freely available as OSP Suite under the GPLv2 License, where source code and content are public. For the calculation and illustration of the PK ratios, Rstudio (R version 3.6.2; R Foundation for Statistical Computing, Vienna, Austria) was used.

Building and Evaluating the Adult PBPK Models

For amikacin, ciprofloxacin, copanlisib, levonorgestrel, moxifloxacin, regorafenib, and rivaroxaban, building and evaluation of the PBPK models have been presented or published previously. The other PBPK models have been used to inform clinical trials. For all compounds that are used in this analysis, an adult PBPK model was created initially and evaluated, as described more recently in the workflow by Maharaj et al and illustrated previously.

Translation of Adult PBPK to Children

Pediatric PBPK models were established using the developed and verified (adult) PBPK model for each compound by translating the adult physiology, clearance process(es), protein binding, and the process-specific variabilities to children (Figure 1). A pediatric translation workflow for constructing a PBPK model in pediatric clinical development has been also illustrated previously. No fitting of the pediatric model parameters was performed. During the translation of adult PBPK models to children, the following assumptions (if unknown) and considerations were made:

- When translating the adult model to children, it is assumed that the contributing metabolism and excretion pathways are qualitatively the same in children as in adults.
- No further changes to model parameters describing drug or drug-biology interacting properties (eg, lipophilicity, intestinal permeability, solubility) are allowed in the PBPK models for children.
- There is identical pathophysiology in children as in adults.

The predictions of the PK parameters in the pediatric subgroups by the PBPK model and the PopPK or NCA of clinical data-based calculations were summarized for each compound as geometric means and used to evaluate predictive performance. Ratios of predicted to observed PK parameters for the evaluated drugs in different pediatric age groups were then investigated for being within a 2-fold error range and within the bioequivalence range (ie, 0.8 ≤ predicted/observed ≤ 1.25). Although a bioequivalence range assessment is meant to demonstrate 2 different formulations to be “equivalent” at a certain dose level, in this analysis it
was applied for PK exposure matching. Therefore, a match-failure would not mean that the whole pediatric dosing approach failed.

**Anthropometric and Physiological Information**

PK-Sim incorporates literature-based age dependencies of anthropometric (eg, height, weight) and physiological (eg, blood flows, organ volumes) parameters, which were generally used as default values for the simulations in children.3,4

The applied ontogeny and variability of active processes and plasma proteins that are built-in into PK-Sim for translation to children are described in the publicly available PK-Sim Ontogeny Database Version 7.3,22 or otherwise referenced for the specific process for each compound.

For each compound, the estimates of the predicted PK parameters in the pediatric subgroups were derived from PBPK modeling. PopPK or NCA models of clinical data were aggregated as geometric means and used for ratio calculation.

**Drug Examples**

Building and evaluation of the adult PBPK models, and the translation to children for 10 small-molecule Bayer compounds was performed as described in the Methods section. Below, a summary of key parameters of the adult PBPK models relevant for development of the pediatric models, and the evaluation of the pediatric models are described.

**Amikacin.** Amikacin is an aminoglycoside antibiotic used for the treatment of a number of serious infections.23

**Adult Model Development.** Amikacin is excreted primarily by glomerular filtration.24,25 The PBPK model for amikacin was previously built for adults and preterm neonates.3,26 As the latter model was built more recently, this PBPK model was evaluated in adults first before predicting the PK in the different pediatric age groups without further changes. Only amikacin PK data after intravenous administration were applied for this analysis, using PK-Sim version 9.1. The available clinical PK data were derived from different literature sources and were here used for PBPK prediction and verification purposes.

**Pediatric Model Evaluation.** The clearance of amikacin in children was predicted purely based on knowledge about kidney maturation3 and, accordingly, developmental changes in glomerular filtration rate (GFR). For evaluating the predictive performance in children, all available reported PK data in children were used. Individual simulations were performed on the basis of the demographics of each child. The predicted clearances were aggregated as geometric means for each predefined age group as described for their comparison with the aggregated reported clearances from literature.27,28 As the clinical study data for amikacin were based on literature data only, the individual PK ratios were additionally calculated and plotted (Figure 2).

**Ciprofloxacin.** Ciprofloxacin belongs to the quinolone antibiotics class, that is used to treat a wide variety of bacterial infections.

**Adult Model Development.** A ciprofloxacin PBPK model was built and evaluated for the predictive performance toward pediatric and geriatric patients, using PK-Sim and MoBi version 7.2.0.15 Both intravenous and orally administered ciprofloxacin PK data were available for analysis. To reflect the known elimination pathways of ciprofloxacin,17 the PBPK model included renal clearance and hepatic clearance. The renal clearance processes were glomerular filtration and an unspecific tubular secretion (TS) accounting for the exceeding renal clearance.29,30 The hepatic clearance processes were cytochrome P450 (CYP) 1A2-mediated elimination31 and an unspecific biliary secretion to account for a suggested rapid gastrointestinal transcellular secretion of ciprofloxacin.32–35 Based on oral PK data in adults, the net active drug uptake and dissolution profiles were estimated, by means of estimating a multiplier for the intestinal permeability of each gastrointestinal tract segment. The formulation and granulate disintegration and dissolution of the oral dose forms were described by a Weibull function. The available reported clinical PK data were derived from different former studies and used to evaluate the PBPK prediction for verification purposes.

**Pediatric Translation.** For evaluating the predictive performance in children, the available reported mean exposures (area under the concentration-time curve [AUC] from time 0 to infinity) in each pediatric age group, mean individual PBPK predictions were made on the basis of the mean demographics of the children.36,37 The estimated exposures were aggregated as geometric means for each predefined age group for their comparison with the aggregated means of the reported exposures.

**Copanlisib.** Copanlisib is a phosphatidylinositol 3-kinase inhibitor that is approved by the US Food and Drug Administration for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least 2 prior systemic therapies.14
Adult Model Development. A PBPK model for copanlisib in adults was created and evaluated using PK-Sim version 8.0. The copanlisib PBPK model includes a hepatic clearance process mediated by CYP3A4, a P-glycoprotein–mediated drug transport, and a hypothetical tissue-binding partner.

Pediatric Translation. The adult PBPK model was translated to children to support clinical decision making of copanlisib application in pediatric patients. Available individual PK data in adolescents were used to calculate an aggregated geometric mean exposure (area under the concentration-time curve from time 0 to 168 hours after the last dose). The PBPK predictions for each individual matched to the adolescent’s demographics were aggregated by calculating the geometric mean of the individual AUC from time 0 to 168 hours after the last dose for the adolescent age group.

Gadovist and Magnevist. Gadovist and magnevist are gadolinium-based extracellular contrast agents and have been proven to be effective contrast media in adults and children for contrast-enhanced magnetic resonance imaging.

Adult Model Development. Gadovist and magnevist are both excreted primarily by glomerular filtration. Gadovist and magnevist that have been applied to support clinical decision making were updated to PK-Sim version 9.0 before simulating the PK for each predefined pediatric age group.

Pediatric Translation. Compared to the original PK-Sim models (version 4) that were used elsewhere, in PK-Sim version 9.0, the method of Hayton, as modified by Edginton et al., is built in to scale glomerular filtration to children. Thereafter, the aggregated geometric mean clearance for each age group was calculated and compared to the available reported (aggregated) clearances for gadovist and magnevist after intravenous administration.

Levonorgestrel. Levonorgestrel is a progestin hormone used in a variety of contraceptive products.

Adult Model Development. A PBPK model was built in PK-Sim version 4.1 for the levonorgestrel contraceptive system intrauterine device in female adults using observed data from clinical studies after intravenous or oral administration of levonorgestrel. An unspecific clearance to account for metabolism was used. The PBPK model included all relevant physiological properties of the uterus and the administration of levonorgestrel by an intrauterine device.

Pediatric Translation. The adult PBPK model was translated to adolescent girls and respective PK parameters for the adolescent postmenarche population were

Figure 2. Individual ratios of predicted to observed clearance for amikacin at different ages. The open circles represent the individual clearance ratios. Black dotted lines indicate 0.5, 1- and 2-fold prediction intervals. Red dotted lines indicate 0.8- and 1.25-fold prediction intervals.
predicted. The aggregated levonorgestrel concentrations after 365 days (geometric mean) were compared to the observed aggregated concentrations (geometric mean values) of the clinical study data.

Moxifloxacin. Moxifloxacin is fluoroquinolone and is applied for the treatment of bacterial infections, such as complicated intra-abdominal infections.

Adult Model Development. A PBPK model for moxifloxacin was built using PK-Sim version 4.2 and MoBi version 2.3 after both oral and intravenous administration of moxifloxacin. The PBPK model includes a renal clearance process mediated by glomerular filtration and 2 hepatic processes, mediated by sulfate conjugation via sulfotransferase 2A1 and glucuronidation via uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A1. An unspecific biliary secretion was included to account for the gastrointestinal transcellular secretion of moxifloxacin and its metabolites. The specific clearance via sulfotransferase 2A1, UGT1A1, and biliary excretion was assumed to be independent of age (ie, the same activity per gram tissue weight as in adults).

Pediatric Translation. The method of Hayton, as modified by Edginton et al, was used to scale the adult GFR to children. For evaluating the predictive performance in children, the PopPK-based results were applied as representative of the observed data, by aggregation of the calculated geometric mean of the individual PopPK clearance estimates from the individual patients for each age group. The PBPK predictions for each individual matched to the individual's demographics were aggregated by calculating the geometric mean of the individual clearances for each predefined age group.

Regorafenib. Regorafenib is an approved oral multitarget inhibitor for the treatment of patients with advanced cancer (colorectal carcinoma, gastrointestinal stromal tumors, and advanced hepatocellular carcinoma).

Adult Model Development. A PBPK model for regorafenib and its active metabolites was built using PK-Sim version 4.2.5 to support dose selection for the pediatric dose-finding study and to estimate exposure based on sparse PK sampling. The PBPK model includes the different processes representing phase I (CYP3A4) and phase II metabolism (UGT1A9) for the parent drug and metabolites implemented in the liver, kidney, and gut lumen. The transport processes for one of the metabolites mediated by P-glycoprotein are covered by clearance processes as well. The model includes estimated individual dissolution profiles to capture the observed high variability in the absorption of regorafenib in adults, considered to be caused by variability in luminal dissolution resulting from interindividual variability in intestinal liquid volumes and bile salt concentrations.

Pediatric Translation. For evaluating the predictive performance in children, the PopPK model-based results were applied, by aggregation of the calculated geometric mean of the individual simulated exposure (AUC from time 0 to 24 hours after the last dose in steady state [AUC$_{24,ss}$]) estimates from the individual patients for each age group. The PBPK predictions for each individual matched to the demographics of the individual patients were aggregated by calculating the geometric mean of the individual AUC$_{24,ss}$ for each predefined age group.

Riociguat. Riociguat is a direct stimulator of the soluble guanylate cyclase and is used to treat 2 forms of pulmonary hypertension: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension in adults.

Adult Model Development. Among other indications, riociguat is under investigation for treatment of PAH in children. A PBPK model for riociguat in adults was built using PK-Sim version 4.2 to predict the PK of riociguat in children of various age groups suffering from PAH following oral administration of multiple doses. The riociguat PBPK model includes renal clearance processes mediated by glomerular filtration and TS. Metabolism of riociguat occurred via oxidative biotransformation by CYP2C8, 2J2, 3A4/3A5, and CYP1A1 into its major metabolite, and to account for the gastrointestinal transcellular secretion unspecific biliary secretion were included.

Pediatric Translation. For evaluating the predictive performance in children, available individual through plasma concentrations at steady-state (C$_{tough,ss}$) in adolescents were aggregated into geometric mean C$_{tough,ss}$ for each cohort. The PBPK predictions for each individual matched to the individual's demographics were aggregated by calculating the geometric mean of the individual C$_{tough,ss}$ for the adolescent age group.

Rivaroxaban. Rivaroxaban, an oral anticoagulant (a direct factor Xa inhibitor) used to treat and prevent blood clots, has been approved in adult patients for several thromboembolic disorders.

Adult Model Development. A PBPK model for rivaroxaban was developed using PK-Sim version 4.2 and MoBi version 2.3 and evaluated in adults and children to inform the dosing regimen of rivaroxaban in pediatric patients. The PBPK model already included a model for gastrointestinal transit and absorption,
Figure 3. Ratios of predicted to observed PK parameters for the evaluated drugs in different pediatric age groups. The age groups are sorted in descending order from adolescents (left) to neonates and infants (right). The different colors represent the different compound PK ratios. The different symbols represent the different PK parameters. Black dotted lines indicate 0.5, 1-, and 2-fold prediction intervals. Red dotted lines indicate 0.8- and 1.25-fold prediction intervals. AUC_{0-168h}, area under the concentration-time curve from time 0 to 168 hours; AUC_{24,ss}, area under the concentration-time curve from time 0 to 24 hours after the last dose in steady state; AUC_{inf}, area under the concentration-time curve from time 0 to infinity; C_{365}, levonorgestrel concentration after 365 days; CL, clearance; C_{trough}, trough concentration.

which is part of PK-Sim version 5.0 and higher.\textsuperscript{53,54} The rivaroxaban PBPK model includes 2 renal clearance processes mediated by glomerular filtration and an unspecific TS accounting for the exceeding renal clearance, and 3 hepatic clearance processes, 2 of which are mediated by CYP3A4, CYP2J2, and another CYP-independent hydrolysis of rivaroxaban.\textsuperscript{55–57}

Pediatric Translation. PBPK predictions for children from term neonates (≥2 kg) to adolescents aged 18 years were aggregated by calculating the geometric mean of the individual exposure (AUC_{24,ss}) for each predefined age group and compared to the aggregated geometric mean of the PopPK-based individual AUC_{24,ss} estimates for each age group, that were used as representative of the observed data.\textsuperscript{52}

Results

The available clinical study data and their reported PopPK or NCA of clinical data-based calculations of the compounds were collected for available age groups (Table 1).

For the individual clearances of amikacin, resulting overall predictivity of the PBPK model in children is exemplarily shown in Figure 2. All individual clearance ratios (n = 33) fell within a 2-fold error range, with 64% (n = 21) within the bioequivalence range (Figure 2). The overall geometric mean fold error was calculated to be 1.22.

The aggregated mean ratios for each compound were successfully predicted for all age groups where observed data were available (neonates and infants, preschool children, school children, and adolescents). Figure 3 shows the mean PK parameter ratios of the investigated compounds predicted in different pediatric age groups. Figures 4 and 5 additionally illustrate the results separately for drugs where either the primary or secondary PK parameters were used for their evaluation in different pediatric age groups. For all compounds, the 27 calculated PK ratios in all pediatric age groups were predicted within a 2-fold error range, with 67% (n = 18) of the predicted ratios being within the bioequivalence range. The highest overestimation and underestimation of an observed PK parameter was observed in the youngest age group (for rivaroxaban and moxifloxacin, respectively).

Comparing PK ratios of only passively eliminated compounds (9 ratios for 3 compounds) with actively eliminated compounds (18 for 7 compounds), as shown
Ince et al

Figure 4. Ratios of predicted to observed primary PK parameters for the evaluated drugs in different pediatric age groups. The age groups are sorted in descending order from adolescents (left) to neonates and infants (right). The different colors represent the different compound PK ratios. The different symbols represent the different PK parameters. Black dotted lines indicate 0.5, 1-, and 2-fold prediction intervals. Red dotted lines indicate 0.8- and 1.25-fold prediction intervals. CL, clearance.

Discussion

PBPK predictions for small-molecule drugs in children are well established in drug development, in particular to support and streamline clinical decisions during drug development in children (eg, specification of dosing regimens, sampling schemes, cohort size). This is also reflected by the constantly high number of this application scenario in submissions to the US Food and Drug Administration. The aim of this methodological study was to further evaluate the application of pediatric PBPK models in drug development. To this end, this study evaluated the predictive performance of pediatric PBPK models for 10 small-molecule compounds developed by Bayer with clinical data in pediatrics. An evaluation metric, the ratio of predicted to observed PK parameters estimated in different pediatric age groups, was selected and used to assess, visualize, and compare the overall predictive power of the 10 PBPK models for the different age groups (Figure 3).

In case of ratio comparison with calculated PK parameters such as AUC and clearance, when data were sparse, observed PK parameters were not derived through NCA of clinical data but from PopPK simulations. The PopPK estimates were assumed to adequately represent the actual PK of the respective study data.

All 27 estimated PK parameter ratios (100%) fell within a 2-fold error range, and 18 ratios (67%) fell within the bioequivalence range, indicating that the overall predictive performance of the pediatric PBPK models was adequate (Figure 3). The error in the predicted PK ratios appeared to increase as age decreased, but it also did not exceed the 2-fold error range in the youngest group. Among the investigated drugs, no bias for systematic over- or underestimation of the PK ratios was evident (Figure 4 and 5). Overall, these findings are comparable to those previously presented in a retrospective analysis on CYP-metabolized drugs using PK-Sim.

For drugs eliminated exclusively via glomerular filtration (amikacin, gadovist, and magnevist), observed PK data were available for all 4 age groups, although not for every drug in each of these age groups (Figure 4). The comparison of the individual ratios of predicted to observed PK parameters for amikacin...
illustrated that passive elimination over the entire pediatric range was well described (Figure 2). Ontogeny of absorption, distribution, metabolism, and elimination processes implemented in PK-Sim were previously evaluated, and are documented on the OSP GitHub website. In the applied PBPK models, either only passive (renal) elimination or combined passive and active elimination was involved. In this analysis, the PBPK approach was successfully applied for the intended use as illustrated in Figure 4 using compounds developed by Bayer.

For most of the investigated compounds, total body clearance comprised several elimination pathways (eg, biliary clearance, metabolism via multiple enzymes), which lessens the suitability of using these drugs as marker compounds for the maturation of a specific clearance process. Additionally, for most of the compounds, not all active processes were known. In these cases, elimination was modeled partly via processes that were not fully characterized, for example, as metabolism without further specification of the responsible enzyme or TS mediated by an unknown efflux transporter. In doing so, the specific activity of the enzyme/transporter normalized to organ weight of the adult PBPK model was assumed to be unchanged in the pediatric model. Absolute clearance was then affected only by age-related changes in the weight of the organ where the process occurred (eg, liver or kidney), but not by additional maturation of the intrinsic clearance (eg, enzyme tissue concentration). The adequate predictive performance for these drugs corroborates the assumption that at least the major part of total clearance is not qualitatively different between children and adults, as this would have likely resulted in substantial over- or underestimation of a drug’s PK ratio.

As not all possible active processes (eg, different transporters or other CYP substrates), or large molecule drugs were evaluated, additional studies for other compounds could further evaluate the predictive model performance in children. Especially in the youngest age group where the maturational changes are highest, and where, although predicted within 2-fold error range, the highest overestimation and underestimation of the observed PK parameter was observed (Figures 3–5). This could help to fill the knowledge gaps in ontogenies that were not addressed here, as reported elsewhere. Additionally, a subcategorization
of children <2 years of age, which are most affected by maturation, should be explored.

Although interindividual variability was included in the PBPK predictions, in this methodological study, the focus was set on the mean predictive performance of PBPK to support adequate dosing in pediatric clinical trials. As a next step, prediction of variability could be further investigated to not only cover the typical pediatric patient, but the full population range as shown exemplarily for amikacin (Figure 2).

The presented findings demonstrate that the confidence in pediatric PBPK models is generally reasonable for small-molecule drugs. Although oral absorption was not in the focus of the present analysis, a limitation of pediatric PBPK models is the lack of a fully mechanistic description of the processes pertaining to drug dissolution and absorption. Although numerous pediatric PBPK model for orally administered drugs can be found in the literature,10 important knowledge gaps remain.10,59 For the orally administered compounds in this analysis (eg, rivaroxaban and ciprofloxacin), dissolution was described by an empirical Weibull function with relevant parameters in this function being fitted in the adult PBPK model.13,15 Typically, new (suspension) formulations need to be developed for children who cannot swallow the tablet given to adults (eg, for rivaroxaban and riociguat). For the majority of published models, the drug release kinetics implemented in the model were not reported, and specific oral dosage forms administered to children were rarely explicitly accounted for.

With the recently increasing interest in developing (semi)mechanistic models for drug dissolution and absorption,60–62 many efforts are now directed at further improving dissolution and absorption modeling.63,64 Adopting a more mechanistic approach to drug release in children, dissolution kinetics could be measured in vitro in biorelevant media that reflect the gastrointestinal physiology in children65,66 and described using a (semi)mechanistic dissolution model, which is then integrated in a whole-body pediatric PBPK model.

**Conclusions**

This study presents a condensed experience of applying pediatric PBPK modeling to internally developed drugs for supporting important clinical decisions. The findings demonstrate that the PK of the 10 small-molecule compounds was adequately predicted in different pediatric age groups. This illustrates the predictive power of PBPK for guiding dosing schemes for compounds in the pediatric population. As a next step, a specific focus on the inclusion and description of variability
should be studied. Ultimately, thoroughly validated PBPK models for children could routinely support drug development programs, thereby catalyzing the speed, efficacy, and success rate of pediatric drug development.

Acknowledgments
The authors thank Leanda Stoian and Maximilian Becker for their support improving the language in the article. All listed authors meet the criteria for authorship and were involved in the analysis and interpretation of the data.

Conflicts of Interest
This work has not been published elsewhere. All co-authors are Bayer employees and potential stock owners. Some of the authors use Open Systems Pharmacology software in their professional role. There are no other arrangements of financial nature, or of any other kind, that could lead to conflict of interests with regard to this manuscript.

Disclosures
Bayer is fully committed to publicly disclose information about its clinical trials in humans. Public disclosure of clinical trial information is done in line with the position of the global pharmaceutical industry associations laid down in the “Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases”. (For more information see https://clinicaltrials.bayer.com/transparency-policy.)

References
1. Zhang X, Yang Y, Grimstein M, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions to the US FDA’s office of clinical pharmacology. J Clin Pharmacol. 2020;60(suppl 1):S160-S178.
2. FDA. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended pediatric study plans. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended. (2020) Accessed August 12 2020.
3. Claassen K, Thelen K, Coboeken K, et al. Development of a physiologically-based pharmacokinetic model for preterm neonates: evaluation with in vivo data. Curr Pharm Des. 2015;21(39):5688-5698.
4. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013-1034.
5. Ince I, Solodenko J, Frechen S, et al. Predictive pediatric modeling and simulation using ontogeny information. J Clin Pharmacol. 2019;59(suppl 1):S95-S103.
6. Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT: Pharmacometrics Syst Pharmacol. 2014;3:e150.
7. Kuepfert L, Niederalt C, Wendt T, et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT: Pharmacometrics Syst Pharmacol. 2016;5(10):516-531.
8. Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91(5):926-931.
9. Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455-464.
10. Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Pharmacol Ther. 2020;211:107541.
11. Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT. State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development. Clin Pharmacokinet. 2019;58(1):1-13.
12. FDA. Clinical pharmacology and biopharmaceutics review of NDA 203159: levonorgestrel-releasing intrauterine system (LCS12) FDA. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203159Orig1s000ClinPharmR.pdf. (2013) Accessed August 12 2020.
13. Ploeger B, Grevel J, Frede M, et al. Evaluation of exposure of rgorafenib and its metabolites in pediatric patients by modeling, simulation, and clinical study. Ann Oncol. 2016;27(6):526–544.
14. Schleuter J, Grevel J, Frechen S, et al. Physiologically-based pharmacokinetic and clinical study to assess effects of CYP3A induction and inhibition on copanlisib PK in cancer patients. Clin Pharmacol Ther. 2019;105(1):70–70.
15. Schleuter JF, Teutonico D, Coboeken K, et al. A physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life. Clin Pharmacokinet.. 2018;57(12):1613-1634.
16. Willmann S, Becker C, Burghaus R, et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet. 2014;53(1):89-102.
17. Willmann S, Frei M, Sutter G, et al. Application of physiologically-based and population PK modeling for dose finding and confirmation during the pediatric development of moxifloxacin. CPT: Pharmacometrics Syst Pharmacol. 2019;8(9):654–663.
18. EMA. Guideline on good pharmacovigilance practices (GVP), Product- or Population-Specific Considerations IV: Paediatric population. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-iv_en-0.pdf. (2018) Accessed August 12 2020.
19. FDA. Pediatric Exclusivity study age group. 2014. https://www.fda.gov/drugs/data-standards-manual-monographs/pediatric-exclusivity-study-age-group. (2014) Accessed August 12 2020.
20. Lippert J, Burghaus R, Edginton A, et al. Open Systems Pharmacology Community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT: Pharmacometrics Syst Pharmacol. 2019;8(12):878-882.
21. Open Systems Pharmacology (OSP). http://www.open-systems-pharmacology.org. Accessed August 12 2020.
22. Open-Systems-Pharmacology (OSP). PK-Sim Ontogeny Database: https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38e7f713b384ec25fa0ce402f1addf32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf. Accessed August 12 2020.
23. Santre C, Georges H, Jacquier JM, et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. *Antimicrob Agents Chemother*. 1995;39(1):264-267.

24. Allegraert K, Cossee V, Langhendries JP, et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. *Biol Neonate*. 2004;86(3):207-211.

25. Brajanoski G, Hoogmartens J, Allegraert K, Adams E. Determination of amikacin in cerebrospinal fluid by high-performance liquid chromatography with pulsed electrochemical detection. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2008;867(1):149-152.

26. Wendl T, Niederalt C, Becker C, et al. Modeling of renal failure, dialysis, inhalation and mechanical ventilation: Development of a whole-body physiologically-based pharmacokinetic (PBPK) model for ICU patients with and without renal failure receiving inhalatively administered Amikacin via a tracheal tube. Presented at: The Annual Meeting of the Population Approach Group in Europe Athen. 2011; Abstr. 2194.

27. Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G. Non-invasive determination of amikacin in cerebrospinal fluid by high-performance liquid chromatography with pulsed electrochemical detection. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2008;867(1):149-152.

28. Vogeizl B, Kowarski A, Lietman PS. The pharmacokinetics of amikacin in children. *J Pediatr*. 1977;91(2):333-339.

29. Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transport 3 (Oat3/SLC22A8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. *Mol Pharmacol*. 2008;74(1):122-131.

30. Alvarez AI, Perez M, Prieto JG, Molina AJ, Merino G. Fluoroquinolone efflux mediated by ABC transporters. *J Pharm Sci*. 2006;97(9):3483-3493.

31. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. *Clin Pharmacol Ther*. 2004;76(6):598-606.

32. Sorgel F, Naber KG, Jaehde U, Reiter A, Seelmann R, Sigl G. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. *Am J Med*. 1989;87(5A):628-656.

33. Bergan T, Dallhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. *Infection*. 1988;16(suppl 1):S3-S13.

34. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. *Clin Pharmacol Ther*. 1995;58(5):532-541.

35. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. *Diagn Microbiol Infect Dis*. 1990;13(2):127-133.

36. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. *Antimicrob Agents Chemother*. 1992;36(5):1086-1090.

37. Peltola H, Ukkonen P, Saxen H, Stass H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. *Pediatrics*. 1998;101(4 Pt 1):658-662.

38. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. *Invest Radiol*. 2009;44(12):776-783.

39. Kunze C, Mentzel HJ, Krishnamurthy R, et al. Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. *Invest Radiol*. 2016;51(1):50-57.

40. Taheri S, Shah NJ, Rosenberg GA. Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging. *Magn Reson Imaging*. 2016;34(7):1034-1040.

41. Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. *AAPS PharmSci*. 2000;2(1):E3.

42. Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. *Clin Pharmacokinet*. 2006;45(7):683-704.

43. FDA. Levonorgestrel FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021225s019lbl.pdf. (2008) Accessed August 12 2020.

44. Wirth S, Emil SGS, Engelis A, et al. Moxifloxacin in pediatric patients with complicated intra-abdominal infections: results of the MOXIPEDIA randomized controlled study. *Pediatr Infect Dis J*. 2018;37(8):e207-e213.

45. Stass H, Lettieri J, Vanveski KM, et al. Pharmacokinetics, safety, and tolerability of single-dose intravenous moxifloxacin in pediatric patients: dose optimization in a phase I study. *J Clin Pharmacol*. 2019;59(5):654-667.

46. Dhillon S. Regorafenib: a review in metastatic colorectal cancer. *Drugs*. 2018;78(11):1133-1144.

47. Geoerger B, Morland B, Jimenez I, et al. Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies. *J Clin Oncol*. 2016;34(15 suppl):abstract 10542.

48. Liu T, Jiang X, Jing ZC. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. *Drug Des Dev Ther*. 2017;11:1195-1207.

49. Bayer AG. Riociguat in children with pulmonary arterial hypertension (PAH) (PATENT-CHILD). https://clinicaltrials.gov/ct2/show/NCT02562235. (2015) Accessed August 12 2020.

50. Saleh S, Becker C, Frey R, Muck W. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *Pulm Circ*. 2016;6(suppl 1):S86-S86.

51. FDA. Rivaroxaban FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf. (2018) Accessed August 12 2020.

52. Willman S, Thelen K, Kubita D, et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. *Thromb J*. 2018;16:32.

53. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part I: oral solutions. *J Pharm Sci*. 2011;100(12):5324-5345.

54. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. *J Pharm Sci*. 2012;101(3):1267-1280.

55. Weinz C, Schwarz T, Kubita D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. *Drug Metab Dispos*. 2009;37(5):1056-1063.

56. Kubita D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. *Br J Clin Pharmacol*. 2010;70(5):703-712.
57. Bayer Pharma AG. Xarelto® (rivaroxaban) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. (2008) Accessed August 12 2020.

58. Yun YE, Edginton AN. Model qualification of the PK-Sim(R) pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. J Toxicol Environ Health Part A. 2019;82(14):789-814.

59. Stillhart C, Vucicevic K, Augustijns P, et al. Impact of gastrointestinal physiology on drug absorption in special populations—an UNGAP review. Eur J Pharm Sci. 2020;147:105280.

60. Pepin XJH, Parrott N, Dressman J, et al. Current state and future expectations of translational modeling strategies to support drug product development, manufacturing changes and controls: a workshop summary report. J Pharm Sci. 2020;110(2):555–566.

61. Gray VA, Mann JC, Barker R, Pepin XJ. The case for physiologically based biopharmaceutics modelling (PBBM): what do dissolution scientists need to know? Development. 2020;12:14.

62. Zhang X, Duan J, Kesisoglou F, et al. Mechanistic oral absorption modeling and simulation for formulation development and bioequivalence evaluation: report of an FDA public workshop. CPT: Pharmacometrics Syst Pharmacol. 2017;6(8):492-495.

63. Miao L, Mousa YM, Zhao L, Raines K, Seo P, Wu F. Using a physiologically based pharmacokinetic absorption model to establish dissolution bioequivalence safe space for oseltamivir in adult and pediatric populations. AAPS J. 2020;22(5):107.

64. Vaidyanathan S, Wang X, Crison J, et al. Bioequivalence comparison of pediatric dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharm Sci. 2019;108(1):741-749.

65. Villiger A, Stillhart C, Parrott N, Kuentz M. Using physiologically based pharmacokinetic (PBPK) modelling to gain insights into the effect of physiological factors on oral absorption in paediatric populations. AAPS J. 2016;18(4):933-947.

66. Maharaj AR, Edginton AN, Fotaki N. Assessment of age-related changes in pediatric gastrointestinal solubility. Pharm Res. 2016;33(1):52-71.